|
1
|
Kirkpatrick B, Fenton WS, Carpenter WT Jr
and Marder SR: The NIMH-MATRICS consensus statement on negative
symptoms. Schizophr Bull. 32:214–219. 2006.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Huhn M, Nikolakopoulou A, Schneider-Thoma
J, Krause M, Samara M, Peter N, Arndt T, Bäckers L, Rothe P,
Cipriani A, et al: Comparative efficacy and tolerability of 32 oral
antipsychotics for the acute treatment of adults with multi-episode
schizophrenia: A systematic review and network meta-analysis.
Lancet. 394:939–951. 2019.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Buchanan RW: Persistent negative symptoms
in schizophrenia: An overview. Schizophr Bull. 33:1013–1022.
2007.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Căpățînă O and Micluția I: Internalized
stigma as a predictor of quality of life in schizophrenia. J Evid
Based Psychother. 19:35–53. 2018.
|
|
5
|
Rabinowitz J, Levine SZ, Garibaldi G,
Bugarski-Kirola D, Berardo CG and Kapur S: Negative symptoms have
greater impact on functioning than positive symptoms in
schizophrenia: Analysis of CATIE data. Schizophr Res. 137:147–150.
2012.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Salvan H, Stanculete M and Macrea R:
Frequency of sexual dysfunction in patients with schizophrenia. Eur
Psychiatry. 22 (Suppl)(S138)2007.
|
|
7
|
Bobes J, Arango C, Garcia-Garcia M and
Rejas J: CLAMORS Study Collaborative Group. Prevalence of negative
symptoms in outpatients with schizophrenia spectrum disorders
treated with antipsychotics in routine clinical practice: Findings
from the CLAMORS study. J Clin Psychiatry. 71:280–286.
2010.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Tsapakis EM, Dimopoulou T and Tarazi FI:
Clinical management of negative symptoms of schizophrenia: An
update. Pharmacol Ther. 153:135–147. 2015.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Murphy BP, Chung YC, Park TW and McGorry
PD: Pharmacological treatment of primary negative symptoms in
schizophrenia: A systematic review. Schizophr Res. 88:5–25.
2006.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Buchanan RW, Breier A, Kirkpatrick B, Ball
P and Carpenter WT Jr: Positive and negative symptom response to
clozapine in schizophrenic patients with and without the deficit
syndrome. Am J Psychiatry. 155:751–760. 1998.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Puia IC, Stanculete MF, Hopulele-Petri A,
Muresan D and Puia A: Patients' perception of weight-related stigma
in a Romanian sample. J Evid Based Psychother. 17:147–157.
2017.
|
|
12
|
Asenjo Lobos C, Komossa K, Rummel-Kluge C,
Hunger H, Schmid F, Schwarz S and Leucht S: Clozapine versus other
atypical antipsychotics for schizophrenia. Cochrane Database Syst
Rev. (CD006633)2010.PubMed/NCBI View Article : Google Scholar
|
|
13
|
McEvoy JP, Lieberman JA, Stroup TS, Davis
SM, Meltzer HY, Rosenheck RA, Swartz MS, Perkins DO, Keefe RS,
Davis CE, et al: CATIE Investigators: Effectiveness of clozapine
versus olanzapine, quetiapine, and risperidone in patients with
chronic schizophrenia who did not respond to prior atypical
antipsychotic treatment. Am J Psychiatry. 163:600–610.
2006.PubMed/NCBI View Article : Google Scholar
|
|
14
|
Liang Y and Yu X: Effectiveness of
amisulpride in Chinese patients with predominantly negative
symptoms of schizophrenia: A subanalysis of the ESCAPE study.
Neuropsychiatr Dis Treat. 13:1703–1712. 2017.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Krause M, Zhu Y, Huhn M, Schneider-Thoma
J, Bighelli I, Nikolakopoulou A and Leucht S: Antipsychotic drugs
for patients with schizophrenia and predominant or prominent
negative symptoms: A systematic review and meta-analysis. Eur Arch
Psychiatry Clin Neurosci. 268:625–639. 2018.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Marder S, Fleischhacker WW, Earley W, Lu
K, Zhong Y, Németh G, Laszlovszky I, Szalai E and Durgam S:
Efficacy of cariprazine across symptom domains in patients with
acute exacerbation of schizophrenia: Pooled analyses from 3 phase
II/III studies. Eur Neuropsychopharmacol. 29:127–136.
2019.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Pilla Reddy V, Kozielska M, Suleiman AA,
Johnson M, Vermeulen A, Liu J, de Greef R, Groothuis GM, Danhof M
and Proost JH: Pharmacokinetic-pharmacodynamic modelling of
antipsychotic drugs in patients with schizophrenia: Part II: The
use of subscales of the PANSS score. Schizophr Res. 146:153–161.
2013.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Shafti SS and Gilanipoor A: A comparative
study between olanzapine and risperidone in management of
schizophrenia. Schizophr Res Treat. 2014(307202)2014.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Balaraman R and Gandhi H: Asenapine, a new
sublingual atypical antipsychotic. J Pharmacol Pharmacother.
1:60–61. 2010.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Potkin SG, Cohen M and Panagides J:
Efficacy and tolerability of asenapine in acute schizophrenia: A
placebo- and risperidone-controlled trial. J Clin Psychiatry.
68:1492–1500. 2007.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Potkin SG, Phiri P, Szegedi A, Zhao J,
Alphs L and Cazorla P: Long-term effects of asenapine or olanzapine
in patients with persistent negative symptoms of schizophrenia: A
pooled analysis. Schizophr Res. 150:442–449. 2013.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Fleischhacker W, Galderisi S, Laszlovszky
I, Szatmári B, Barabássy Á, Acsai K, Szalai E, Harsányi J, Earley
W, Patel M and Németh G: The efficacy of cariprazine in negative
symptoms of schizophrenia: Post hoc analyses of PANSS individual
items and PANSS-derived factors. Eur Psychiatry. 58:1–9.
2019.PubMed/NCBI View Article : Google Scholar
|
|
23
|
Earley W, Guo H, Daniel D, Nasrallah H,
Durgam S, Zhong Y, Patel M, Barabássy Á, Szatmári B and Németh G:
Efficacy of cariprazine on negative symptoms in patients with acute
schizophrenia: A post hoc analysis of pooled data. Schizophr Res.
204:282–288. 2019.PubMed/NCBI View Article : Google Scholar
|
|
24
|
Lasser RA, Dirks B, Nasrallah H, Kirsch C,
Joseph Gao, Pucci ML, Knesevich MA and Lindenmayer JP: Adjunctive
lisdexamfetamine dimesylate therapy in adult outpatients with
predominant negative symptoms of schizophrenia: Open label and
randomized controlled trial. Soc Psychiatry Psychiatr Epidemiol.
38:2140–2149. 2013.PubMed/NCBI View Article : Google Scholar
|
|
25
|
Lindenmayer JP, Nasrallah H, Pucci M,
James S and Citrome L: A systematic review of psychostimulant
treatment of negative symptoms of schizophrenia: Challenges and
therapeutic opportunities. Schizophr Res. 147:241–252.
2013.PubMed/NCBI View Article : Google Scholar
|
|
26
|
Goff DC: D-cycloserine: An evolving role
in learning and neuroplasticity in schizophrenia. Schizophr Bull.
38:936–941. 2012.PubMed/NCBI View Article : Google Scholar
|
|
27
|
de Bartolomeis A, Sarappa C, Magara S and
Iasevoli F: Targeting glutamate system for novel antipsychotic
approaches: Relevance for residual psychotic symptoms and treatment
resistant schizophrenia. Eur J Pharmacol. 682:1–11. 2012.PubMed/NCBI View Article : Google Scholar
|
|
28
|
Umbricht D, Alberati D, Martin-Facklam M,
Borroni E, Youssef EA, Ostland M, Wallace TL, Knoflach F,
Dorflinger E, Wettstein JG, et al: Effect of bitopertin, a glycine
reuptake inhibitor, on negative symptoms of schizophrenia: A
randomized, double-blind, proof-of-concept study. JAMA Psychiatry.
71:637–646. 2014.PubMed/NCBI View Article : Google Scholar
|
|
29
|
Singer P, Dubroqua S and Yee BK:
Inhibition of glycine transporter 1: The yellow brick road to new
schizophrenia therapy? Curr Pharm Des. 21:3771–3787.
2015.PubMed/NCBI View Article : Google Scholar
|
|
30
|
Mazinani R, Nejati S and Khodaei M:
Effects of memantine added to risperidone on the symptoms of
schizophrenia: A randomized double-blind, placebo-controlled
clinical trial. Psychiatry Res. 247:291–295. 2017.PubMed/NCBI View Article : Google Scholar
|
|
31
|
Rezaei F, Mohammad-Karimi M, Seddighi S,
Modabbernia A, Ashrafi M, Salehi B, Hammidi S, Motasami H,
Hajiaghaee R, Tabrizi M and Akhondzadeh S: Memantine add-on to
risperidone treatment of negative symptoms in patients with stable
schizophrenia. J Clin Psychopharmacol. 33:336–342. 2013.PubMed/NCBI View Article : Google Scholar
|
|
32
|
de Lucena D, Fernandes BS, Berk M, Dodd S,
Medeiros DW, Pedrini M, Kunz M, Gomes FA, Giglio LF, Lobato MI, et
al: Improvement of negative and positive symptoms in
treatment-refractory schizophrenia: A double-blind, randomized,
placebo-controlled trial with memantine as add-on therapy to
clozapine. J Clin Psychiatry. 70:1416–1423. 2009.PubMed/NCBI View Article : Google Scholar
|
|
33
|
Kishi T, Matsuda Y and Iwata N: Memantine
add-on to antipsychotic treatment for residual negative and
cognitive symptoms of schizophrenia: A meta-analysis.
Psychopharmacology (Berl). 234:2113–2125. 2017.PubMed/NCBI View Article : Google Scholar
|
|
34
|
Ritsner MS, Bawakny H and Kreinin A:
Pregnenolone treatment reduces severity of negative symptoms in
recent-onset schizophrenia: An 8-week, double-blind, randomized
add-on two-center trial. Psychiatry Clin Neurosci. 68:432–440.
2014.PubMed/NCBI View Article : Google Scholar
|
|
35
|
Momtazmanesh S, Zare-Shahabadi A and
Rezaei N: Cytokine alterations in schizophrenia: An updated review.
Front Psychiatry. 10(892)2019.PubMed/NCBI View Article : Google Scholar
|
|
36
|
Laan W, Grobbee DE, Selten JP, Heijnen CJ,
Kahn RS and Burger H: Adjuvant aspirin therapy reduces symptoms of
schizophrenia spectrum disorders: Results from a randomized,
double-blind, placebo-controlled trial. J Clin Psychiatry.
71:520–527. 2010.PubMed/NCBI View Article : Google Scholar
|
|
37
|
Cho M, Lee TY, Kwak YB, Yoon YB, Kim M and
Kwon JS: Adjunctive use of anti-inflammatory drugs for
schizophrenia: A meta-analytic investigation of randomized
controlled trials. Aust N Z J Psychiatry. 53:742–759.
2019.PubMed/NCBI View Article : Google Scholar
|
|
38
|
Çakici N, van Beveren NJM, Judge-Hundal G,
Koola MM and Sommer IEC: An update on the efficacy of
anti-inflammatory agents for patients with schizophrenia: A
meta-analysis. Psychol Med. 49:2307–2319. 2019.PubMed/NCBI View Article : Google Scholar
|
|
39
|
Schmidt L, Phelps E, Friedel J and
Shokraneh F: Acetylsalicylic acid (aspirin) for schizophrenia.
Cochrane Database Syst Rev. 8(CD012116)2019.PubMed/NCBI View Article : Google Scholar
|
|
40
|
Breier A, Liffick E, Hummer TA, Vohs JL,
Yang Z, Mehdiyoun NF, Visco AC, Metzler E, Zhang Y and Francis MM:
Effects of 12-month, double-blind N-acetyl cysteine on symptoms,
cognition and brain morphology in early phase schizophrenia
spectrum disorders. Schizophr Res. 199:395–402. 2018.PubMed/NCBI View Article : Google Scholar
|
|
41
|
Farokhnia M, Azarkolah A, Adinehfar F,
Khodaie-Ardakani MR, Hosseini SM, Yekehtaz H, Tabrizi M, Rezaei F,
Salehi B, Sadeghi SM, et al: N-acetylcysteine as an adjunct to
risperidone for treatment of negative symptoms in patients with
chronic schizophrenia: A randomized, double-blind,
placebo-controlled study. Clin Neuropharmacol. 36:185–192.
2013.PubMed/NCBI View Article : Google Scholar
|
|
42
|
Sepehrmanesh Z and Heidary M, Akasheh N,
Akbari H and Heidary M: Therapeutic effect of adjunctive N-acetyl
cysteine (NAC) on symptoms of chronic schizophrenia: A
double-blind, randomized clinical trial. Prog Neuropsychopharmacol
Biol Psychiatry. 82:289–296. 2018.PubMed/NCBI View Article : Google Scholar
|
|
43
|
Berk M, Copolov D, Dean O, Lu K, Jeavons
S, Schapkaitz I, Anderson-Hunt M, Judd F, Katz F, Katz P, et al:
N-acetyl cysteine as a glutathione precursor for schizophrenia-a
double-blind, randomized, placebo-controlled trial. Biol
Psychiatry. 64:361–368. 2008.PubMed/NCBI View Article : Google Scholar
|
|
44
|
Zhang L, Zheng H, Wu R, Zhu F, Kosten TR,
Zhang XY and Zhao J: Minocycline adjunctive treatment to
risperidone for negative symptoms in schizophrenia: Association
with pro-inflammatory cytokine levels. Prog Neuropsychopharmacol
Biol Psychiatry. 85:69–76. 2018.PubMed/NCBI View Article : Google Scholar
|
|
45
|
Oya K, Kishi T and Iwata N: Efficacy and
tolerability of minocycline augmentation therapy in schizophrenia:
A systematic review and meta-analysis of randomized controlled
trials. Hum Psychopharmacol. 29:483–491. 2014.PubMed/NCBI View Article : Google Scholar
|
|
46
|
Bennett AC and Vila TM: The role of
ondansetron in the treatment of schizophrenia. Ann Pharmacother.
44:1301–1306. 2010.PubMed/NCBI View Article : Google Scholar
|
|
47
|
Samadi R, Soluti S, Daneshmand R, Assari S
and Manteghi AA: Efficacy of risperidone augmentation with
ondansetron in the treatment of negative and depressive symptoms in
schizophrenia: A randomized clinical trial. Iran J Med Sci.
42:14–23. 2017.PubMed/NCBI
|
|
48
|
Kishi T, Mukai T, Matsuda Y and Iwata N:
Selective serotonin 3 receptor antagonist treatment for
schizophrenia: Meta-analysis and systematic review. Neuromolecular
Med. 16:61–69. 2014.PubMed/NCBI View Article : Google Scholar
|
|
49
|
Davidson M, Saoud J, Staner C, Noel N,
Luthringer E, Werner S, Reilly J, Schaffhauser JY, Rabinowitz J,
Weiser M and Luthringer R: Efficacy and safety of MIN-101: A
12-week randomized, double-blind, placebo-controlled trial of a new
drug in development for the treatment of negative symptoms in
schizophrenia. Am J Psychiatry. 174:1195–1202. 2017.PubMed/NCBI View Article : Google Scholar
|
|
50
|
Singh SP, Singh V, Kar N and Chan K:
Efficacy of antidepressants in treating the negative symptoms of
chronic schizophrenia: Meta-analysis. Br J Psychiatry. 197:174–179.
2010.PubMed/NCBI View Article : Google Scholar
|
|
51
|
Rummel C, Kissling W and Leucht S:
Antidepressants for the negative symptoms of schizophrenia.
Cochrane Database Syst Rev: CD005581, 2006 doi: 10.1002/14651858
D005581.
|
|
52
|
Möller HJ: Management of the negative
symptoms of schizophrenia: New treatment options. CNS Drugs.
17:793–823. 2003.PubMed/NCBI View Article : Google Scholar
|
|
53
|
Caforio G, Di Giorgio A, Rampino A, Rizzo
M, Romano R, Taurisano P, Fazio L, De Simeis G, Ursini G, Blasi G,
et al: Mirtazapine add-on improves olanzapine effect on negative
symptoms of schizophrenia. J Clin Psychopharmacol. 33:810–812.
2013.PubMed/NCBI View Article : Google Scholar
|
|
54
|
Cho SJ, Yook K, Kim B, Choi TK, Lee KS,
Kim YW, Lee JE, Suh S, Yook KH and Lee SH: Mirtazapine augmentation
enhances cognitive and reduces negative symptoms in schizophrenia
patients treated with risperidone: A randomized controlled trial.
Prog Neuropsychopharmacol Biol Psychiatry. 35:208–211.
2011.PubMed/NCBI View Article : Google Scholar
|
|
55
|
Tsai CH, Chen TT and Huang WL: Combination
of escitalopram and aripiprazole causes significant improvement of
negative symptoms of simple schizophrenia. Psychiatry Clin
Neurosci. 68:582–583. 2014.PubMed/NCBI View Article : Google Scholar
|
|
56
|
Hinkelmann K, Yassouridis A, Kellner M,
Jahn H, Wiedemann K and Raedler TJ: No effects of antidepressants
on negative symptoms in schizophrenia. J Clin Psychopharmacol.
33:686–690. 2013.PubMed/NCBI View Article : Google Scholar
|
|
57
|
Usall J, López-Carrilero R, Iniesta R,
Roca M, Caballero M, Rodriguez-Jimenez R, Oliveira C, Bernardo M,
Corripio I, Sindreu SD, et al: Double-blind, placebo-controlled
study of the efficacy of reboxetine and citalopram as adjuncts to
atypical antipsychotics for negative symptoms of schizophrenia. J
Clin Psychiatry. 75:608–615. 2014.PubMed/NCBI View Article : Google Scholar
|
|
58
|
Nikbakhat MR, Arabzadeh S, Zeinoddini A,
Khalili Z, Rezaei F, Mohammadinejad P, Ghaleiha A and Akhondzadeh
S: Duloxetine add-on to risperidone for treatment of negative
symptoms in patients with stable schizophrenia: Randomized
double-blind placebo-controlled study. Pharmacopsychiatry.
49:162–169. 2016.PubMed/NCBI View Article : Google Scholar
|
|
59
|
Ding N, Li Z and Liu Z: Escitalopram
augmentation improves negative symptoms of treatment resistant
schizophrenia patients-A randomized controlled trial. Neurosci
Lett. 681:68–72. 2018.PubMed/NCBI View Article : Google Scholar
|
|
60
|
Conley RR, Boggs DL, Kelly DL, McMahon RP,
Dickinson D, Feldman S, Ball MP and Buchanan RW: The effects of
galantamine on psychopathology in chronic stable schizophrenia.
Clin Neuropharmacol. 32:69–74. 2009.PubMed/NCBI View Article : Google Scholar
|
|
61
|
Choi KH, Wykes T and Kurtz MM: Adjunctive
pharmacotherapy for cognitive deficits in schizophrenia:
Meta-analytical investigation of efficacy. Br J Psychiatry.
203:172–178. 2013.PubMed/NCBI View Article : Google Scholar
|
|
62
|
Singh J, Kour K and Jayaram MB:
Acetylcholinesterase inhibitors for schizophrenia. Cochrane
Database Syst Rev. 1(CD007967)2012.PubMed/NCBI View Article : Google Scholar
|
|
63
|
Hayes E, Gavrilidis E and Kulkarni J: The
role of estrogen and other hormones in the pathophysiology and
treatment of schizophrenia. Schizophr Res Treat.
2012(540273)2012.PubMed/NCBI View Article : Google Scholar
|
|
64
|
Kulkarni J, de Castella A, Headey B,
Marston N, Sinclair K, Lee S, Gurvich C, Fitzgerald PB and Burger
H: Estrogens and men with schizophrenia: Is there a case for
adjunctive therapy? Schizophr Res. 125:278–283. 2011.PubMed/NCBI View Article : Google Scholar
|
|
65
|
Begemann MJ, Dekker CF, van Lunenburg M
and Sommer IE: Estrogen augmentation in schizophrenia: A
quantitative review of current evidence. Schizophr Res.
141:179–184. 2012.PubMed/NCBI View Article : Google Scholar
|
|
66
|
Modabbernia A, Rezaei F, Salehi B,
Jafarinia M, Ashrafi M, Tabrizi M, Hosseini SM, Tajdini M, Ghaleiha
A and Akhondzadeh S: Intranasal oxytocin as an adjunct to
risperidone in patients with schizophrenia: An 8-week, randomized,
double-blind, placebo-controlled study. CNS Drugs. 27:57–65.
2013.PubMed/NCBI View Article : Google Scholar
|
|
67
|
Oya K, Matsuda Y, Matsunaga S, Kishi T and
Iwata N: Efficacy and safety of oxytocin augmentation therapy for
schizophrenia: An updated systematic review and meta-analysis of
randomized, placebo-controlled trials. Eur Arch Psychiatry Clin
Neurosci. 266:439–450. 2016.PubMed/NCBI View Article : Google Scholar
|
